RU2453554C2 - Замещенные производные эстратриена как ингибиторы 17бета hsd - Google Patents
Замещенные производные эстратриена как ингибиторы 17бета hsd Download PDFInfo
- Publication number
- RU2453554C2 RU2453554C2 RU2009124589/04A RU2009124589A RU2453554C2 RU 2453554 C2 RU2453554 C2 RU 2453554C2 RU 2009124589/04 A RU2009124589/04 A RU 2009124589/04A RU 2009124589 A RU2009124589 A RU 2009124589A RU 2453554 C2 RU2453554 C2 RU 2453554C2
- Authority
- RU
- Russia
- Prior art keywords
- trien
- compound
- group
- alkyl
- formula
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 46
- 230000001419 dependent effect Effects 0.000 claims abstract 17
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 claims abstract 3
- 230000005764 inhibitory process Effects 0.000 claims abstract 3
- 239000003270 steroid hormone Substances 0.000 claims abstract 3
- 108090000790 Enzymes Proteins 0.000 claims abstract 2
- 102000004190 Enzymes Human genes 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 36
- -1 substituted Chemical class 0.000 claims 29
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 25
- 201000010099 disease Diseases 0.000 claims 20
- 241000124008 Mammalia Species 0.000 claims 18
- 208000035475 disorder Diseases 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 14
- 238000011282 treatment Methods 0.000 claims 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 13
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 230000002265 prevention Effects 0.000 claims 12
- 239000003098 androgen Substances 0.000 claims 11
- 229960005309 estradiol Drugs 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 241000282412 Homo Species 0.000 claims 9
- 229930182833 estradiol Natural products 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 229940030486 androgens Drugs 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000003211 malignant effect Effects 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 3
- 208000005641 Adenomyosis Diseases 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 3
- 208000002177 Cataract Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 206010012442 Dermatitis contact Diseases 0.000 claims 3
- 208000005171 Dysmenorrhea Diseases 0.000 claims 3
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 201000009273 Endometriosis Diseases 0.000 claims 3
- 206010020112 Hirsutism Diseases 0.000 claims 3
- 206010027514 Metrorrhagia Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010039792 Seborrhoea Diseases 0.000 claims 3
- 206010039966 Senile dementia Diseases 0.000 claims 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 3
- 206010067269 Uterine fibrosis Diseases 0.000 claims 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 206010000496 acne Diseases 0.000 claims 3
- 206010068168 androgenetic alopecia Diseases 0.000 claims 3
- 201000002996 androgenic alopecia Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 208000010247 contact dermatitis Diseases 0.000 claims 3
- 201000009274 endometriosis of uterus Diseases 0.000 claims 3
- 229940011871 estrogen Drugs 0.000 claims 3
- 239000000262 estrogen Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 201000010260 leiomyoma Diseases 0.000 claims 3
- 208000007106 menorrhagia Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 3
- 239000010802 sludge Substances 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 206010043778 thyroiditis Diseases 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 206010046766 uterine cancer Diseases 0.000 claims 3
- 201000007954 uterine fibroid Diseases 0.000 claims 3
- 102100037426 17-beta-hydroxysteroid dehydrogenase type 1 Human genes 0.000 claims 2
- 102100022586 17-beta-hydroxysteroid dehydrogenase type 2 Human genes 0.000 claims 2
- 108010084625 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 claims 2
- 102100022585 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 101710174214 Estradiol 17-beta-dehydrogenase 2 Proteins 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 125000005620 boronic acid group Chemical class 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 230000009245 menopause Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 101100451537 Caenorhabditis elegans hsd-1 gene Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010053159 Organ failure Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002912 morpholin-4-ylsulfonyl group Chemical group O1C([H])([H])C([H])([H])N(S(=O)(=O)[*])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 abstract 2
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06125138.5 | 2006-11-30 | ||
| EP06125138 | 2006-11-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009124589A RU2009124589A (ru) | 2011-01-10 |
| RU2453554C2 true RU2453554C2 (ru) | 2012-06-20 |
Family
ID=38198108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009124589/04A RU2453554C2 (ru) | 2006-11-30 | 2007-11-27 | Замещенные производные эстратриена как ингибиторы 17бета hsd |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2099814A1 (fr) |
| JP (1) | JP5264760B2 (fr) |
| CN (1) | CN101568547B (fr) |
| AU (1) | AU2007327653B2 (fr) |
| CA (1) | CA2671075A1 (fr) |
| MX (1) | MX2009005201A (fr) |
| RU (1) | RU2453554C2 (fr) |
| WO (1) | WO2008065100A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2688901B1 (fr) * | 2011-03-25 | 2019-05-08 | Université Laval | INHIBITEURS DE 17ß-HSD1, 17ß-HSD3 ET 17ß-HSD10 |
| DE102011083725A1 (de) * | 2011-09-29 | 2013-04-04 | Bayer Pharma AG | Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| WO2013078413A1 (fr) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulateurs du stockage lipidique |
| KR20150036319A (ko) | 2012-07-10 | 2015-04-07 | 바이엘 파마 악티엔게젤샤프트 | 3-치환된 에스트라-1,3,5(10),16-테트라엔 유도체, 그의 제조방법, 이를 포함하는 약학 제제 및 의약품 제조를 위한 그의 용도 |
| US9714266B2 (en) | 2013-02-21 | 2017-07-25 | Bayer Pharma Aktiengesellschaft | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3) |
| AR096728A1 (es) | 2013-06-25 | 2016-01-27 | Forendo Pharma Ltd | Derivados de estratrieno-tiazol terapéuticamente activos |
| US9663549B2 (en) * | 2013-06-25 | 2017-05-30 | Forendo Pharma Ltd. | Therapeutically active 17-nitrogen substituted estratreinthiazole derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase |
| TW201522359A (zh) * | 2013-06-25 | 2015-06-16 | Forendo Pharma Ltd | 治療用活性雌三烯噻唑衍生物 |
| EP3473630B1 (fr) * | 2014-07-02 | 2021-01-13 | Xavier University Of Louisiana | Stratégie de promédicament à base de bore pour une biodisponibilité augmentée et des besoins de dosage inférieur pour des molécules de médicament contenant au moins un groupe phénol (ou hydroxyle aromatique) |
| US10626140B2 (en) | 2014-12-23 | 2020-04-21 | Forendo Pharma Ltd | Prodrugs of 17β-HSD1-inhibitors |
| EP3237431B1 (fr) * | 2014-12-23 | 2019-03-20 | Forendo Pharma Ltd | Promédicaments d'inhibiteurs de la 17 -hsd1 |
| CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
| MX391234B (es) | 2017-06-08 | 2025-03-21 | Forendo Pharma Ltd | Compuestos de estra-1,3,5(10)-trien-17-ona sustituida con 15.beta.-[3-propanamido] y sus 17-oximas para usarse en la inhibicion de 17.beta.-hidroxiesteroides deshidrogenasas. |
| JP7417608B2 (ja) | 2018-12-05 | 2024-01-18 | フォレンド ファーマ リミテッド | １７－ｈｓｄ１阻害剤としての１６（１７）位でピラゾール環と縮合しているエストラ－１，３，５（１０）－トリエン化合物 |
| IT201900004041A1 (it) * | 2019-03-20 | 2020-09-20 | Farmabios Spa | Procedimento per la preparazione di un derivato del fulvestrant |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571933A (en) * | 1994-11-17 | 1996-11-05 | Duquesne University Of The Holy Ghost | Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use |
| US6541463B1 (en) * | 1998-03-11 | 2003-04-01 | Endorecherche, Inc. | Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0025788D0 (en) * | 2000-10-20 | 2000-12-06 | Sterix Ltd | Use |
| TWI331154B (en) * | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
| US8030298B2 (en) * | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| JP5268635B2 (ja) * | 2005-05-26 | 2013-08-21 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | １７β−ＨＳＤ１及びＳＴＳインヒビター |
-
2007
- 2007-11-27 MX MX2009005201A patent/MX2009005201A/es active IP Right Grant
- 2007-11-27 AU AU2007327653A patent/AU2007327653B2/en not_active Ceased
- 2007-11-27 JP JP2009538695A patent/JP5264760B2/ja not_active Expired - Fee Related
- 2007-11-27 CN CN200780048224.8A patent/CN101568547B/zh not_active Expired - Fee Related
- 2007-11-27 CA CA002671075A patent/CA2671075A1/fr not_active Abandoned
- 2007-11-27 WO PCT/EP2007/062856 patent/WO2008065100A1/fr not_active Ceased
- 2007-11-27 EP EP07847383A patent/EP2099814A1/fr not_active Withdrawn
- 2007-11-27 RU RU2009124589/04A patent/RU2453554C2/ru not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571933A (en) * | 1994-11-17 | 1996-11-05 | Duquesne University Of The Holy Ghost | Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use |
| US6541463B1 (en) * | 1998-03-11 | 2003-04-01 | Endorecherche, Inc. | Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use |
Non-Patent Citations (1)
| Title |
|---|
| AHVED et al // Bioorg. & Med. Chem. v. 14 no 24, p.8564-8573. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101568547A (zh) | 2009-10-28 |
| RU2009124589A (ru) | 2011-01-10 |
| JP5264760B2 (ja) | 2013-08-14 |
| AU2007327653A1 (en) | 2008-06-05 |
| MX2009005201A (es) | 2009-05-27 |
| AU2007327653B2 (en) | 2013-04-18 |
| WO2008065100A1 (fr) | 2008-06-05 |
| CN101568547B (zh) | 2014-06-25 |
| JP2010511010A (ja) | 2010-04-08 |
| CA2671075A1 (fr) | 2008-06-05 |
| EP2099814A1 (fr) | 2009-09-16 |
| HK1134298A1 (en) | 2010-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2453554C2 (ru) | Замещенные производные эстратриена как ингибиторы 17бета hsd | |
| RU2412196C2 (ru) | ИНГИБИТОРЫ 17β-ГСД1 И СТС | |
| CN105873917B (zh) | 含有吡啶基部分的非甾体类抗雄激素和选择性雄激素受体调节剂 | |
| BR112013023028B1 (pt) | Composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e formulação farmacêutica tópica | |
| WO2003027105A1 (fr) | 3-pyridyl thiophenes substitues en tant qu'inhibiteurs de la lyase c17,20 | |
| BR112012018246B1 (pt) | Compostos de amida reversa como inibidores de proteína desacetilase, composição farmacêutica compreendendo os referidos compostos, kit e usos dos mesmos | |
| KR101130556B1 (ko) | Ｈｄａｃ 억제제로서의 설포닐피롤 | |
| JP2008545678A5 (fr) | ||
| CN105592888A (zh) | 用于治疗疾病的kdm1a抑制剂 | |
| JP2010511010A5 (fr) | ||
| JP2013527238A (ja) | チトクロームｐ４５０阻害剤およびその使用 | |
| BR112015020963B1 (pt) | compostos derivados de 2-acilaminotiazola, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos | |
| JP2015522050A (ja) | ３−置換エストラ−１，３，５（１０），１６−テトラエン誘導体、その調製法、これらを含む医薬製剤および医薬を調製するためのその使用 | |
| JP6134072B2 (ja) | キサンチンオキシダーゼ阻害薬 | |
| US20040267017A1 (en) | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors | |
| CA2135056A1 (fr) | Nouveaux 17b-a substituant-4-aza-5a-andros-tan-3-ones olefiniques en delta-17 et delta-20 et satures, servant d'inhibiteurs de la 5a-reductase | |
| US20040236110A1 (en) | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | |
| JP2010535156A (ja) | ウイルスポリメラーゼ阻害剤 | |
| US7662842B2 (en) | Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents | |
| EP3237430B1 (fr) | PROMÉDICAMENTS D'INHIBITEURS DE 17ß -HSD1 | |
| CN110945007B (zh) | 用于抑制17β-羟基类固醇脱氢酶的15β-[3-丙酰氨基]-取代的雌-1,3,5(10)-三烯-17-酮化合物及其17-肟 | |
| EP3541812B1 (fr) | Composés agonistes de mglur7 pour le traitement de maladies, troubles ou états régulés par mglur7 | |
| KR20250028370A (ko) | 이작용성 화합물 및 이작용성 화합물을 포함하는 약제학적 조성물, 및 이를 사용하여 안드로겐 수용체 관련 질환을 치료하기 위한 방법 | |
| EP1926487A2 (fr) | Amides de thiazolidinone, amides d'acide carboxylique de thiazolidine et amides de sérine, y compris leurs conjugués de polyamines, en tant qu'agents anti-cancéreux sélectifs | |
| US20120095055A1 (en) | HEXAHYDROCYCLOPENTYL[f]INDAZOLE 5-HYDROXYMETHYL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20151128 |